Mayo Clinic’s Precure Research: Aiming to Predict Disease Before Symptoms Arise

Mayo Clinic researchers are combining biological, environmental and health data with artificial intelligence to identify changes that may signal disease years before clinical symptoms appear.

Diseases like Alzheimer's, heart failure, and cancer often remain undiagnosed for years, with biological processes happening unnoticed long before patients exhibit any signs. Mayo Clinic aims to change that by identifying these silent transitions through its Precure Research initiative.

This ambitious research effort targets diseases affecting critical organs, including the brain, heart, kidneys, liver, and lungs. By integrating a wealth of data from genetic profiles, biological specimens, medical histories, environmental factors, and real-time data from wearable devices, the initiative hopes to pinpoint early disease indicators.

The paramount goal? To catch diseases in their earliest stages, thus improving treatment outcomes. To achieve this, the team faces complex inquiries: Which biological changes reliably signal the onset of disease? What can clinicians effectively act upon?

Recent breakthroughs are encouraging. A major genetic study at Mayo identified inherited risk factors for cancer and cardiovascular disease in nearly 2,000 participants, many of whom had no prior acknowledgment of their risks. Moreover, certain precancerous changes can now be detected years before cancer manifests, and Alzheimer’s biomarkers can be analyzed decades ahead of cognitive decline.

Together, these findings advance a compelling vision: transforming healthcare from reactive treatment to proactive disease prediction and prevention.

Dr. Vijay Shah, Mayo Clinic's Kinney executive dean of research, articulates this transformative shift as a reflection of Mayo’s historical focus on addressing unmet patient needs with actionable knowledge. "Our research and practice are intertwined; we aim to prioritize patient needs above all," he states.

Heidi Dieter, the chief research administrator, underscores the potential redefinition of patient-care dynamics. "We’re not merely treating diseases anymore; we're collaborating with individuals throughout their entire health journeys," she explains.

The Invisible Years

Traditionally, physicians encounter diseases only after significant biological changes have already occurred. Be it detectable tumors, declining kidney function, or the emergence of memory deficits, clinical diagnoses come too late in the disease's timeline.

Biological changes precede these symptoms, as alterations in proteins, metabolism, immune responses, and environmental exposures leave measurable traces. The intention behind Precure Research is to reconstruct this process, combining data on genes, proteins, metabolites, and immune signals with long-term medical records and lifestyle factors.

A recipient of a genetic variant associated with higher disease risk might remain healthy for years or even a lifetime. Therefore, researchers strive to discern the transition from genetic predisposition to clinical illness and identify the pivotal moments when intervention could be beneficial.

However, uncovering a biological signal linked to disease isn't synonymous with creating an effective screening tool. The goal is to discern these signals to develop screening technologies that empower early intervention, optimizing treatment efficacy.

Beyond DNA

Mayo’s approach transcends traditional physiology. Researchers have broadened their focus to encompass the exposome—the cumulative effect of environmental and lifestyle factors on an individual. These influences range from diet and exercise to exposure to pollutants and chemicals, all of which can leave biological signatures detectable in blood and other samples.

Pilot studies are investigating how chronic exposure to air pollution may affect transplant outcomes and how environmental chemicals could alter medication responses. They’re also exploring saliva-based biosensors to detect biological changes linked to head and neck cancers.

Building a Biological Time Machine

Executing this multifaceted research requires an unprecedented infrastructure, leading to the ambition of creating the largest integrated collection of biological specimens combined with health information through the Mayo Clinic Platform. This system connects findings in blood or tissue specimens to molecular measures, environmental data, and extensive clinical histories.

The ultimate goal is to recreate each patient’s biological road to disease. By linking molecular data with comprehensive clinical contexts, Mayo Clinic is well-positioned to foster research across various disorders, using insights gleaned from one area to inform approaches in another.

AI plays a pivotal role in managing the overwhelming amount of data. The potential relationships between variables are too intricate for manual exploration. AI tools can identify patterns across genetic variants, proteins, clinical data, and environmental metrics that standard analytics might overlook.

A Historic Institution Embraces the Future

Mayo Clinic’s rich history offers a solid foundation for the ambitious scope of Precure Research. For over 160 years, the institution has been dedicated to enhancing patient care, building a collaborative model that prioritizes the patient’s needs. Innovations such as the group medical practice and longitudinal medical records have transformed care delivery and empowered physicians to think beyond singular snapshots of patient health.

The undertakings of Precure Research aim to sustain this legacy, pushing forward into a new epoch of medical management.

The Difference is the Resolution

While longitudinal records allowed insights into a patient’s health over time, Precure Research hopes to illuminate the biological subtleties that underpin those histories. This initiative also celebrates patient engagement in research, as their clinical data and biological samples can reveal patterns otherwise obscured.

By continually contributing this information, patients can aid researchers in comprehending the transition from health to disease, opening the door for proactive health preservation strategies that benefit future generations.

From Predicting Disease to Preventing It

Ultimately, the scope of Precure Research reaches far beyond early diagnosis, enabling studies into underlying biological processes such as inflammation and metabolic dysfunction. A patient later diagnosed with heart failure, for example, may exhibit shared biological pathways with conditions like kidney disease or dementia much earlier in their health journey. Recognizing these connections offers physicians a chance to intervene before irreversible damage occurs.

Mayo aims to extend the healthspan, the duration of a person’s life marked by well-being, free from chronic disease or disability. This requires understanding not just who is at risk of developing certain diseases, but also identifying pivotal moments for intervention and the most effective strategies to alter these trajectories.

Ultimately, the next wave of medical advancement may stem not from singular pharmaceutical breakthroughs, but from a comprehensive grasp of human health that sidesteps disease altogether.

The post Can disease be identified before symptoms begin? Mayo Clinic researchers are looking for answers appeared first on Mayo Clinic News Network.